NCT01449591View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Erythemato-telangiectatic Rosacea
Interventions
DRUG

BFH772 1% ointment

DRUG

Vehicle ointment

DRUG

Noritate® 1% cream

Trial Locations (6)

Unknown

Novartis Investigative Site, Hot Springs

Novartis Investigative Site, Ann Arbor

Novartis Investigative Site, Paramus

Novartis Investigative Site, Portland

Novartis Investigative Site, Austin

Novartis Investigative Site, Spokane

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY